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Abstract
We developed a nanotechnology based-cell mediated drug delivery system by loading myelin antigen-specific T cells with
nanoparticles bound to anti-CD20 monoclonal antibody. Anti-CD20 antibody is a current treatment (ocrelizumab) for multiple
sclerosis (MS), a chronic, inflammatory and autoimmune disease of the central nervous system (CNS). CD20-depletion has been
associated with efficacy in active relapsing and progressive MS, but may not efficiently target inflammatory cells compartmen-
talized in the CNS. In our work, the intravenous transfer of T cells containing nanoparticle-anti-CD20 complex in mice causes B
cell depletion in the spleen and in the brain, whereas the injection of anti-CD20 alone depletes B cells only in the spleen. Testing
this system in Experimental Autoimmune Encephalomyelitis (EAE), animal model of MS, we found that spinal cord B cell
depletion ameliorates the disease course and pathology.
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Introduction
Nanoparticles-based drug delivery systems (NDDS) have
been a point of interest because of their low cost, good biode-
gradability, ease of synthesis and for their capability to load
and release active molecules beyond the blood-brain barrier
(BBB) (Nance et al. 2014; Zhang et al. 2016). Furthermore,
the chemical functionalization of NDDS has been extensively
exploited to enhance central nervous system (CNS) cargoes
concentration (Zhou et al. 2018).
However, one of the major issues in the use of NDDS is the
poor ability of these materials to specifically target the site of
interest (Li et al. 2018), since a systemic treatment dispersion
is generally observed. To overcome this hurdle, cell-mediated
NDDS have been developed, in which immune cells are suited
as “Trojan horse” and loaded with drugs of interest to release
them beyond the BBB (Batrakova et al. 2011; Ballerini et al.
2015). Indeed, the greatest obstacle to the access of drugs to
the CNS is the presence of physiological barriers, such as the
BBB and the blood-spinal cord barrier (BSCB) (Goyal et al.
2014; Batrakova and Kabanov 2013). Since only small lipid
soluble molecules with a molecular weight < 400 Da are
allowed to cross the BBB, a large amount of treatments used
for neurological morbidities are ineffective when this barrier is
closed (Dong 2018); thus, new strategies for an effective brain
drug delivery system are strongly needed.
In previous work, we demonstrated that iron-oxide nano-
particles (NBR) enter T cells in vitro without exerting toxic
effects. Moreover, we showed that nanoparticle-loaded T cells
efficiently migrate and release NBR to the CNS parenchyma
when i.v. transferred either into naïve recipient mice, in which
the BBB is intact, or in mice characterized by an impaired
BBB due to the induction of Experimental Autoimmune
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Encephalomyelitis (EAE), animal model ofMultiple Sclerosis
(MS) (D’Elios et al. 2018).
Here, we developed a T cell mediated drug delivery system
by loading MOG35–55 antigen specific T cells with NBR
nanoparticles functionalized on their surface with the mono-
clonal antibody anti-CD20 (NBR-anti-CD20). We tested
in vivo this T cell-NBR-anti-CD20 complex for its capability
to deplete B cells in the periphery and in the CNS of mice
during EAE.
Our work showed that the i.v. transfer of autoantigen spe-
cific T cells loaded with NBR-anti-CD20 depletes B cells in
the spleen and in the spinal cord of mice, whereas anti-CD20
alone depletes B cells only in the spleen.
Results
T Cells Are Successfully Loaded with NBR-Anti-CD20
Complex
In previous work, we showed that pristine NBR enter T cells
upon 2 h of incubation (D’Elios et al. 2018). In the present
study, we first investigated whether NBR functionalized with
the antibody anti-CD20 are also able to enter T lymphocytes.
Figure 1a shows that, after 2 h of incubation, around 85% (see
Methods) of T cells are loaded with nanoparticles.
Furthermore, more than 88% of loaded T cells are alive
(Fig. 1b). We conclude that NBR-anti-CD20 complex is
quickly loaded by T cells in the absence of clear signs of cell
toxicity.
T Cells Loaded with NBR-Anti-CD20 Complex Deplete
Peripheral B Cells
A second set of experiments was designed to compare the
ability of the neutralizing anti-CD20 antibody to in vivo de-
plete B cells when complexed to NBR and injected i.v. by
passive transfer of T cells containing the NBR-anti-CD20
complex.
We used two groups of animals that were injected i.v. (see
Methods) with the anti-CD20 antibody alone or with T cells
loaded with NBR-anti-CD20 complex. After 9 and 17 days
from the injection, we collected the spleens of the treated mice
in order to evaluate the CD19+ cells depletion and compared
the results among the groups of animals.
Notably, after 9 days from the injection these values are
comparable, suggesting that NBR-anti-CD20 loaded T cells
may migrate to the spleen and efficiently release their
nanoparticle-cargo containing the monoclonal antibody; fur-
thermore, as expected, no CD19+ depletion is observed in
control groups (Fig. 2a, c). In a second time point, after
17 days, spleen percentage of CD19+ cells was of 36.5 in
NBR-anti-CD20-treated mice and of 30.3 in anti-CD20-
treated mice (Fig. 2b).
Iron-Oxide Specific Staining Confirms NBR Delivery in
the CNS
Crucial to our hypothesized exploitation of T cells in their
ability to deliver their nanoparticle-cargoes into the CNS, in
particular in diseased animals, we previously showed that T
cells (CD3+) loaded with NBR reached the spinal cord in
either naïve and EAE mice (D’Elios et al. 2018).
Here, we confirm this finding, showing the presence of
NBR nanoparticles in the CNS of NBR-anti-CD20 treated
EAE mice (Fig. 3c, d). NBR were not detected in PBS-
treated mice, used as negative controls (Fig. 3a, b).
NBR-Anti-CD20 Complex Loaded into T Cells Depletes
B Cells in Mice Spinal Cord
We decided to further exploit our EAEmodel to verify wheth-
er the injection of anti-CD20 antibody alone or as a
nanoparticle-cargo in T cells succeeded in depleting B cells
within the CNS. This is particularly interesting since the path-
ogenic role of B cells in MOG35–55-induced EAE is a matter
of debate. Besides, B cells form part of the CNS infiltrate
during the disease, thus MOG35–55-induced EAE represents
a unique model to investigate the efficacy of the anti-CD20-
mediated B cell depletion in the CNS.
In Fig.3e–o, we report the quantification of the amount of B
cells in the spinal cord infiltrates in all the experimental
groups: Fig. 3e) animals treated with PBS; Fig. 3f) animals
treated with T cells loaded with NBR-anti-CD20; Fig. 3g)
animals treated with anti-CD20 and Fig. 3h) animals treated
with T cells loaded with NBR-isotype (NBR-ISO) control.
We found differences among groups, with the presence of
B cells aggregates (Fig. 3i–n) within the cellular infiltrates in
the subarachnoid space and in the white matter of control
groups, whereas NBR-anti-CD20 group exhibited only sparse
B cells that generally failed to aggregate (Fig. 3f, l). We then
quantified B220+ cells/mm2 in spinal cords of each group of
mice (Fig. 4o). Results show that a significant (p < 0.001;
p < 0.0001) B cell depletion is present in NBR-anti-CD20-
treated animals compared to all other groups. We did not find
any significant difference among the other experimental
groups. These data strongly support the hypothesis that
NBR-anti-CD20 complex loaded in T cells efficiently migrate
in the spinal cord and to release the anti-CD20 antibody,
which depletes B cells in spinal cord infiltrates. Conversely,
anti-CD20 alone might not reach the CNS in a sufficient ther-
apeutic concentration. Of note, NBR-antibody complexes
were prepared using a concentration of anti-CD20 equal to
the concentration of anti-CD20 antibody alone (see Methods).
Spinal Cord B Cell Depletion Ameliorates EAE Course
Next, we compared the clinical course of the disease
among the different groups of animals to validate this
nanoparticle-mediated therapeutic strategy. Despite the
controversial role of B cells in MOG35–55 EAE model,
we document a milder clinical course of the disease when
B cells are depleted from the spinal cord. In Fig. 4, a
comparison among the clinical score of the four groups
is depicted: NBR-anti-CD20-treated mice (Fig. 4, blue
line) display a significant (p < 0.05) lower disability when
compared to PBS-treated animals (Fig. 4, yellow line).
This finding strengthens the hypothesis that the route of
neutralizing antibody administration is crucial to amelio-
rate EAE.
NBR-Anti-CD20 Treatment Limits Spinal Cord
Demyelination and Infiltrates
Accordingly with clinical findings, the evaluation of in-
flammatory infiltrates in the CNS of EAE mice assessed
by histological H&E staining (Fig. 5a, first row) high-
lights the differences between NBR-anti-CD20-treated
Fig. 1 Evaluation by
fluorescence microscopy and
viability of T cells loaded with
fluorescent NBR-anti-CD20. a
Fluorescence microscopy of T
cells (isolated from naïve C57BL/
6 mice) after the incubation for
2 h with fluorescent NBR-anti-
CD20. Upper pictures show
DAPI staining for cells nuclei (in
blue) and NBR fluorescence
(fluorescein 488, in green). Lower
pictures show CD3+ T cells (in
red) and the merged image (scale
bar = 20 μm; 40X). b Analysis by
flow cytometry of the viability of
T cells incubated with fluorescent
NBR-anti-CD20 for 2 h and la-
belled with propidium iodide (PI)
to detect necrotic cells. In the dot
plot, the percentage of necrotic T
cells loaded with fluorescent
NBR-anti-CD20 (NBR Fluo-
aCD20 + PI+) is reported in the
gate Q2. One experiment repre-
sentative of three independent
ones is shown
mice and the other groups in terms of number, extension
and tissue distribution of cell infiltrates.
In NBR-anti-CD20-treated mice, infiltrates in spinal cord
sections are small, rare and display a perivascular location.
Fig. 2 Spleen B cells depletion in mice analyzed by flow cytometry after
9 and 17 days from treatments. a Flow cytometry dot plots report the
percentages of CD19+ (gate Q1 in each plot) and CD3+ cells (gate Q4 in
each plot) within the spleen of a mouse from control group (PBS-treated;
left plot), anti-CD20 group (middle plot) and fromNBR-anti-CD20 group
(right plot) at 9 days post injection. b Flow cytometry dot plots report the
percentages of CD19+ and CD3+ cells within the spleen of a mouse from
control group (PBS-treated; left plot), anti-CD20 group (middle plot) and
fromNBR-anti-CD20 group (right plot) at 17 days post injection. cGraph
reports the percentage of CD19+ cells, analyzed by flow cytometry, at
9 days post injection in CTRL mice group (PBS-treated), NBR-anti-
CD20-treated mice and anti-CD20-treated mice. One experiment of three
independent ones is shown. Each group consists in three–four mice.
Mean ± SEM is reported. Mann-Whitney statistical test was used
(**p < 0.01; ***p < 0.001)
Based on these differences, we assigned a histological score
(see Methods) (Giuliani et al. 2005) to provide a semi-
quantitative evaluation (Fig. 5b).
Our results show that the histological score attributed to
NBR-anti-CD20-treated mice is significantly (p < 0.01) lower
than the other groups; specifically, there is a smaller amount of
inflammatory foci and a less parenchymal infiltration.
In Fig. 5a (second row), we report an example of LFB/PAS
staining, used to assess the state of spinal cord demyelination,
a hallmark of the disease. Results show that NBR-anti-CD20-
treated mice present less demyelination. Accordingly, the de-
myelination score (see Methods) is lower (p < 0.05) in NBR-
anti-CD20-treated mice compared to the other groups (Fig.
5b).
In addition, the evaluation of astrogliosis, performed by
glial fibrillary acidic protein (GFAP, a cytoskeletal marker
for astroglia) labelling revealed a limited astrogliosis within
the NBR-anti-CD20 group (Fig. 5a, third row) compared to
others. Wemay conclude that NBR-anti-CD20-treatment, and
not anti-CD20 alone, ameliorates EAE pathology.
The Spinal Cord of NBR-Anti-CD20-Treated Mice
Shows a Higher Percentage of Neurons and no Axonal
Damage
We investigated the number of NeuN+ cells and the axonal
damage in the spinal cord of EAEmice and then compared the
results among the four groups of treatments. The analysis of
NeuN+ cells by immunofluorescence (Fig. 6a) and the paired
quantification by manual count (Fig. 6b) shows a significantly
higher NeuN+ percentage in NBR-anti-CD20-treated EAE
mice compared to all the other groups (CTRL, anti-CD20
and NBR-ISO).
In parallel, the qualitative evaluation of the axonal damage
by Bielschowsky staining (Fig. 7) shows a generally better
axonal state in the spinal cord of NBR-anti-CD20-treatedmice
compared to the other groups.
Autoreactive T Cell Transfer Does Not Alter the
Peripheral Production of pro-Inflammatory Cytokines
during EAE
To gain insight into the effect of NBR-anti-CD20 loaded T
cells during EAE, we then investigated the levels of pro-
inflammatory cytokines involved in EAE pathogenesis
(IFN-γ and IL-17 (D’Elios et al. 2018)) from cells isolated
from mice draining lymph nodes after in vitro stimulation
(Fig. 8a–d).
Our data do not show a difference between IFN-γ (Fig.
8a, b) and IL-17 (Fig. 8c, d) production among groups, indi-
cating that autoreactive T cells injection is not altering the
production of pathogenic cytokines from peripheral
encephalitogenic T cells. Furthermore, EAE amelioration
does not follow a decreased peripheral release of pathogenic
cytokines.
Spleen Cells from NBR-Treated Mice Show a Lower
In Vitro Proliferative Response
We next evaluated the ex vivo proliferative response of
splenocytes from EAE mice (Fig. 8e). Results show a signif-
icantly (p < 0.05; p < 0.01) reduced proliferation (about 1.5–2
folds lower) in NBR-anti-CD20- and NBR-ISO-treated mice
compared to PBS- and anti-CD20-treated groups after in vitro
cells stimulation with MOG35–55.
Discussion and Conclusion
In the present study, we show that nanoparticles bound to the
neutralizing anti-CD20 antibody enter T cells without exerting
any toxic effect (Fig. 1) and, once tested in vivo, efficiently
mediate B cell depletion within mice spleen (Fig. 2), as it
happens after the injection of anti-CD20 alone. Furthermore,
our study demonstrates that T cells loaded with NBR-anti-
CD20 complex migrate to the CNS during EAE and signifi-
cantly reduces the number of B cells in spinal cord infiltrates
(Fig. 3), whereas the injection of anti-CD20 alone is ineffec-
tive. Finally, we found that this novel, cell-mediated drug
delivery system ameliorates the clinical course of EAE (Fig.
4), preserving neurons (Fig. 6) and the axonal state (Fig. 7) of
the CNS of EAE mice.
Developing a complex T cell mediated drug delivery sys-
tem to target B cells in the CNS, we demonstrated that T cells
are an efficient mean of drug delivery in the brain, which is
normally difficult to target. Indeed, the percentage of depleted
B cell in mice spleen (Fig. 2d) suggests that T cells loaded
with NBR-anti-CD20 partially release the cargo in the periph-
ery, where injected cells arrive through the blood flow,
eliciting a peripheral B cell depletion as much as anti-CD20
alone. In our work, the peripheral depletion of B lymphocytes
does not impact the clinical course of MOG35–55 induced
EAE, accordingly to previous findings reported in Weber
et al. (2010) and Matsushita et al. (2008). In these studies,
authors investigated the possible role of B cells in EAE path-
ogenesis and demonstrated that mice treated with anti-CD20
exhibit a worsening or an improvement of symptoms, depend-
ing on the adopted protocol of immunization and treatment.
Our observations suggest that in the chronic EAE model the
peripheral B cell depletion is ineffective during the disease
onset. Since we did not observe any clinical worsening of
EAE, it is tempting to speculate that B cells have no regulatory
action in the MOG35–55-induced EAE autoimmune reaction at
10 days post-immunization (d.p.i.). Looking at the data of
infiltrates, we have to underline that the number of infiltrates

and the presence of B cells in CNS infiltrates are two aspects
not forcedly directly related. We may hypothesize that reduc-
tion of infiltrates in these experiments has beneficial effects
when B cells are reduced. On the other hand, other experimen-
tal features may increase brain infiltrates in term of numbers
and components comparing to PBS treated mice: first, the B
cell depletion, when it is limited at the periphery; second, the
inoculation of autoreactive T cells carrying the isotype con-
trol, although not affecting the EAE clinical score, may in-
crease the cells able to migrate into the parenchyma.
Cytokines produced in vitro by MOG35–55 stimulated
lymph nodes T cells are not significantly modulated by the
treatments (Fig. 8a–d). In light of this result, we may conclude
that peripheral MOG35–55-primed T cells are not shifted to-
wards a different phenotype, e.g. inflammatory (Th1) or
regulatory (Th2) in response to the autoreactive-cell injection
or to the B cell depletion, accordingly to experiments per-
formed using different protocols of B cell depletion (Weber
et al. 2010).
The proliferative response of splenocytes is reduced when
T cells loaded with NBR, either functionalized or not with
anti-CD20 antibody, are injected in EAE mice (Fig. 8e).
This may be due to a homeostatic effect of the injected T cells
that, as we know from a previous work, tend to be less immu-
nogenic after nanomaterial endocytosis (D’Elios et al., 2018).
We may speculate that the less proliferating T cells and the
simultaneous B cell depletion in the CNS are both responsible
of the observed amelioration of EAE. In fact, B cell depletion
may determine the failure of the compartmentalized antigen
presentation and, consequently, a lack of sustainment to en-
cephalitogenic T cells. This interpretation is supported by our
results, that revealed a drop of B220+ cells in NBR-anti-
CD20-treated mice (Fig. 3o), suggesting that this treatment
exerts an efficient B cell depletion. Conversely, anti-CD20
alone did not reach CNS in a sufficient therapeutic concentra-
tion, as demonstrated by the higher B cell counts within spinal
cord infiltrates. Furthermore, the amelioration of EAE course
finds supporting evidence in the evaluation of axons and neu-
rons count in the spinal cord of mice groups, as our results
showed a significantly higher percentage of NeuN+ cells in
the CNS of NBR-anti-CD20-treated mice compared to all the
other groups (Fig. 6) and no axonal damage in the same group
of mice (Fig. 7).
The exact mechanism of action of anti-CD20 is still un-
clear, but a combination of factors seems to occur (Glennie
et al. 2007). Indeed, anti-CD20 seems to mainly act through
the cell lysis induced by antibody-dependent cytotoxicity
(ADCC) via monocytes, macrophages or Natural Killer
(NK) FCγR engagement (Boross and Leusen 2012), but the
complement-dependent cytotoxicity (CDC) plays a pivotal
role in the mechanism as well (Glennie et al. 2007), though
several groups excluded the requirement of the complement in
a wide range of rodent models (Hamaguchi et al. 2006;
Nimmerjahn and Ravetch 2006; Uchida et al. 2004).
However, it is likely that, in vivo, a synergic combination of
effector mechanisms takes place at different times during anti-
CD20 treatment, depending on B cell dynamics, time frame of
administration and perhaps also on targeted anatomic com-
partment (Boross and Leusen 2012). Of note, anti-CD20 an-
tibody injected alone does not effectively reach the CNS, as
shown by the higher and residual B cells amount in the spinal
cord after treatment, probably linked to difficulty of large and
hydrophilic molecules, such as monoclonal antibodies, in
reaching CNS by crossing both BBB and BSCB
(Kasinathan et al. 2015). Despite EAE model and MS are
characterized by a partial loss of these biological barriers
(Bennett et al. 2010), the total administered amount of mono-
clonal antibodies that are able to effectively reach the CNS is
Fig. 4 EAE clinical scores. Graph reports EAE mice clinical score,
evaluated daily according to following scale: 0 normal mouse, no overt
signs of disease; 1 limp tail or hind limbweakness but not both; 2 limp tail
and hind limb weakness; 3 partial hind limb paralysis; 4 complete hind
limb paralysis; 5 moribund state; death by EAE. NBR loaded T cells were
i.v injected at 10 days post-immunization d.p.i. Mice were sacrificed at 19
d.p.i. One experiment of two independent ones is shown. Each group
consists in three–four mice. Mean ± SEM is reported. Friedman statistical
test was used (*p < 0.05)
Fig. 3 Spinal cord NBR detection and B cell quantification. Figures a-d
show spinal cord sections of EAE mice observed by optical microscopy
after Perls staining, specific for iron-oxide, to detect the presence of NBR.
Two 40X magnifications (b, d; scale bar =100 μm) of two 20X spinal
cord sections (a, c; scale bar =50 μm) are shown. Blue = iron-oxide de-
posits; red = nuclei; pink = cytoplasm. Black arrows indicate iron-oxide
NBR. e-n Representative images of fluorescent microscopy are showed
in the panel above. Spinal cords from: PBS mice (e, i), NBR-anti-CD20
(f, l), anti-CD20- (g, m) and NBR-ISO- (h, n) treated mice. Sections were
labelled with FITC-B220 anti-mouse monoclonal antibody (in green) and
DAPI (cell nuclei, in blue). Scale bar = 20μm;magnifications = 20X (e, f,
g, h) and 40X (i, l, m, n). Columns in the graph (o) represent B cell
amounts per mm2 in spinal cord sections (approximately, 1 mm2 covers
half spinal cord slice) in NBR-anti-CD20- (left column) and anti-CD20-
treated mice (right column). At least 15 spinal cord’s slices for two mice
of each group were evaluated. Unpaired t-test statistical test was per-
formed. Mean ± SEM of two independent experiments is reported.
Mann-Whitney statistical test was used (***p < 0.001; ****p < 0.0001)
very low, specifically about 0.1% of serum concentration even
if intrathecally administered (Rubenstein et al. 2003). For ex-
ample, Komori et al. (2016) showed that the intrathecal ad-
ministration of Rituximab in MS patients does not provide a
successfully therapeutic depletion of B cells throughout the
CNS tissue, limiting its action only to cerebrospinal fluid.
To sum up, this study showed that NBR-anti-CD20 enter T
cells and that this complex is able to release in vivo the anti-
body both in the periphery and in the CNS of EAE mice. Our
results stressed the need for an exact quantification, in the
future, of the amount of antibody to bind to NBR and to
release in the CNS to treat the disease.
Methods
NBR Synthesis and Functionalization
Magnetite (Fe3O4) nanoparticles (NBR) were synthesized
as previously reported (Patent: Baldi et al., “Magnetic
Nanoparticles functionalized with cathecol, production
and use thereof”, WO/2015 104,664) (Baldi et al. 2015).
Briefly, 40 mL of NPFe suspended in diethylene glycol
was sonicated for 1 h in an ultrasound bath and then a
solution of [N-(3,4-dihydroxyphenethyl) dodecanamide
(DDA)] (1.09 g, 3.2 mmol) dissolved in 120 mL of etha-
nol was slowly added to the glycolic suspension. The
system was again sonicated for 1 h at room temperature.
The solution was then diluted with 60 mL of ultrapure
water, magnetically sedimented and dispersed in 90 mL
of THF (Fe3O4–DDA). Then 440 mg of PGLA-b-PEG-
COOH (43–3 kDa, 9.6 μmmol) was dissolved in 10 mL
of THF and then added to 90 mL of Fe3O4–DDA suspen-
sion (440 mg of Fe3O4). Fluorescent nanoparticles
(Fe3O4-DDA-Fluo) were achieved by first adding a
DMSO solution of Fluorescein 488-NHS (1.25 μmol,
amino reactive) to a solution of 4-aminobutylphosphonic
acid (1.25 μmol, a linker that can react with the carboxyl
of the fluorochrome by its amino group and with the
magnetic core by its phosphonic group) and left reacting
under stirring for 3,5 h. The mixture was then added to
90 mL of Fe3O4-DDA and the suspension was left
reacting overnight at room temperature. The formation
o f NBR F l u o r e s c e n t w a s a c h i e v e d b y t h e
nanoprecipitation method: the organic phase was mixed
to 900 mL of phosphate-buffered solution under vigorous
stirring, maintaining the water/organic ratio 10/1 with a
constant removal of the resulting solution. The mixture
was then purified, by washing with phosphate-buffered
solution, and concentrated (by ultrafiltration, Pellicon
XL, cut-off 500 kDa) to a final volume of 150 mL (con-
centration: 0.3% (w/w) in Fe3O4), then filtered through a
syringe filter (Millipore Sterivex, 0.22 μm, polyethersul-
fone membrane). Purified NBR have a diameter approxi-
mately of 45 nm. Finally, chemical synthesis of NBR-
antiCD20 (UltraLeaf™ purified anti-mouse CD20, clone
SA271G2, Biolegend,USA) or NBR-isotype control anti-
body (NBR-ISO) (UltraLeaf™ purified Rat IgG2b, κ
Isotype Ctrl Antibody, clone RTK4530, Biolegend,
USA) complex was made through a double step reaction:
PGLA-PEG-COOH iron oxide nanoparticles, exposing a
COOH, were activated in a mild acid environment (pH 5)
with 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide
(EDC), obtaining an O-acylisourea. Afterwards, N-
hydroxysulfosuccinimide (Sulfo-NHS) was added at
pH 5, to improve efficiency and to create dry-stable
(amine-reactive) intermediates. EDC couples Sulfo-NHS
to carboxyls, forming an NHS ester that is considerably
more stable than the O-acylisourea intermediate while
allowing for efficient conjugation to primary amines at
physiologic pH (ThermoFisher Scientific). Finally, at
physiological pH, anti-CD20 has been added to NBR,
generating a stable peptide bond (very stable bond up to
pH = 1–2, very strong acidic conditions and heating).
In Vitro Test for NBR Uptake by T Cells
T lymphocytes from naïve C57BL/6 mice were collected from
draining lymph nodes and incubated for 2 h in 6:1 volume
ratio with fluorescent NBR-anti-CD20 at 37 °C (5% CO2).
Cell suspension was washed thrice with PBS for removing
the excess of NBR-anti-CD20 outside the cells and then a drop
of cell suspension was put on a glass slide (15,000 cells/spot)
until dry. Then, spots were covered with paraformaldehyde
4% (PFA 4) for 20 min for cells fixation. Glass slides were
washed thrice with PBS and closed with mounting medium
containing DAPI (Prolong Gold with DAPI, Life
Technologies, USA) for fluorescence microscopy. The per-
centage of NBR positive cells was calculated on a total of 8
observed areas/slide (10,000 cells/slide).
Experimental Animals
Female C57BL/6 mice (Charles River Srl, Italy) were bred in
the CeSaL animal house of the University of Florence, in
Makrolon cages, with free access to food and water and kept
at 23 °C with a 12 h light/dark cycle. Every manipulation of
the animals was executed according to the guidelines of the
European community for animal care (DL 116/92, application
of the European Communities Council Directive 2010/63/EU)
and approved by the Committee for Animal Care (DGSAF,
Italy, Authorization no. 514–2016-PR).
Fig. 5 EAE spinal cord pathology. a Panels show representative images,
for each group, of spinal cord section after H&E staining for
inflammatory infiltrates (black arrows, 4X, scale bar =100 μm), LFB/
PAS for demyelinated areas (black arrows; 4X, scale bar = 100 μm) and
GFAP labelling for astrogliosis (green = GFAP, blue = nuclei; 10X, scale
bar = 100 μm; 20X, scale bar = 50 μm). bHistological score assigned for
the inflammatory infiltrates (left graph) (according to Giuliani et al.
2005): score 0 for no infiltration, score 1 for foci of subarachnoid cell
infiltration, score 2 for subarachnoid infiltration, score 3 for foci of pa-
renchymal infiltrates and score 4 for diffuse and widespread parenchymal
infiltrates. Right graph, demyelination score (Giuliani et al. 2005): 0 no
demyelination; 1 refers to foci of demyelination superficial and proximal
to the subarachnoid space involving less than 25% of the lateral columns;
2 represents foci of demyelination deep in the parenchyma involving over
25% of the lateral columns; 3 denotes diffuse and widespread demyelin-
ation areas. 25 tissue sections/mice were analyzed for each experimental
group in two independent experiments. Mean ± SEM is reported. Mann-




EAE was induced in 8 to 10 weeks-old female mice by sub-
cutaneous (s.c.) injection of 200μg ofmyelin oligodendrocyte
g l y c o p r o t e i n M O G 3 5 – 5 5 p e p t i d e
(MEVGWYRSPFSRVVHLYRNGK, purity 85%; Espikem,
Florence, Italy) in Phosphate Buffer Saline solution (PBS,
Carlo Erba Reagents S.r.l., Italy), emulsified with an equal
volume of complete Freund’s adjuvant (CFA, Sigma) supple-
mented with 7 mg/mL−1 Mycobacterium tuberculosis H37Ra
(Difco Laboratories, USA). Bordetella pertussis toxin
(500 ng) was administered by i.p. injection at days 0 and 2
post immunization (Merck, Germany). All the experiments
with animals were performed blinded and mice were random-
ly assigned to the experimental groups. EAE-induced mice
were scored daily for clinical signs of disease, according to
the following scale: 0) normal mouse, no overt signs of dis-
ease; (1) limp tail or hind limb weakness but not both; (2) limp
tail and hind limb weakness; (3) partial hind limb paralysis;
(4) complete hind limb paralysis; (5) moribund state or death
by EAE: sacrifice for humane reasons. Daily EAE score of
mice groups is reported in Supplementary Table 1.
Loading of MOG35–55 T Cells with NBR Nanoparticles
Mononuclear cells were isolated from draining lymph
nodes of immunized donor mice at 7 d.p.i. by mechani-
cal dissociation on nylon filters with 70 μm pores (BD
Falcon). Cells were seeded in 96-well U bottom plates
(Jet Biofil, China) at a density of 2 × 105/well with
10 μg/mL of MOG35–55 in complete medium (RPMI
1640 + 10% fetal bovine serum +1% penici l l in-
streptomycin +1% sodium pyruvate +1% L-glutamine
+1% Hepes Buffer, Sigma) for 72 h. MOG35–55 reac-
tive T cells (2 × 106 cells/mL) were incubated with NBR-
anti-CD20 or NBR-ISO complex in a ratio of 6:1 for 2 h
at 37 °C (5% CO2). Then, cells were washed three times
with PBS and suspended at 1 × 106/150 μL before i.v.
injection in recipient mice.
Mice Injection
Mice were injected with 26G syringes (BD Plastipak™, USA)
in the tail vein with 150 μL of PBS, T-cells suspension loaded
with NBR-anti-CD20 or NBR-ISO. NBR treated mice re-
ceived 1 × 106 loaded T cells. Last group was injected with
250 μL of anti-CD20 monoclonal antibody (1 mg/mL) alone
(UltraLeaf™ clone SA271G2, Biolegend, USA).
Histopathological and Immunofluorescence
Evaluation
Spinal cord samples were fixed with 4% paraformaldehyde
(PFA) and paraffin-embedded and sectioned with a microtome
in 5 μm thick slices (D’Elios et al., 2018). Slices were stained
with Hematoxylin and Eosin (H&E), Luxol Fast Blue/Periodic
Acid-Schiff (LFB/PAS), Perls (Bio-Optica, Italy) or
Bielschowsky staining, following standard protocols.
Histological score for inflammatory infiltrates was assigned ac-
cording to Giuliani et al. (2005): score 0 for no infiltration, score
1 for foci of subarachnoid cell infiltration, score 2 for subarach-
noid infiltration, score 3 for foci of parenchymal infiltrates and
score 4 for diffuse and widespread parenchymal infiltrates.
Evaluationwas performed on 3mice ormore per group (25 slices
each). The demyelination score was assigned following Giuliani
et al. (2005) as follows: 0 no demyelination present; score 1
refers to foci of demyelination that is superficial and proximal
to the subarachnoid space and that involves less than 25% of
lateral columns; 2 represents foci of deep parenchymal demye-
lination and involves over 25% of the lateral columns; 3 denotes
a widespread demyelination. Alternatively, selected slices were
chosen for immunofluorescence. Briefly, slices were rehydrated
with xylene for 5 min (renewing twice the solution) and with a
descending degree ethanol series (100°, 90°, 75° and 50°, 3 min
each) till deionized water (MilliQ). Afterwards, slices were im-
mersed in a sodium borohydride (NaBH4, Sigma) 1% solution
for 10 min, in order to quench intrinsic auto-fluorescence of
formalin-fixed paraffin-embedded tissues. Then, the slices were
left in citrate buffer (citric acid 10 mM, pH= 6; Sigma) at 95 °C
for 20min and then cooled for 20min at RT for antigen retrieval,
permeabilized with PBS/ FBS 5%/ Triton 0.3% (Sigma,
Germany) for 30 min at RT and labelled for 2 h in the dark at
RT with anti-mouse FITC-CD45R/B220 monoclonal antibody
(1:200, clone RA3-6B2, BD Pharmingen, USA) diluted in per-
meabilization buffer. Alternatively, slices were stained overnight
with a primary GFAP rat anti-mouse monoclonal antibody
(1:500, clone 2.2B10, Thermo Fisher Scientific, USA) or with
NeuN Polyclonal Antibody (1:500, Thermo Fisher Scientific,
USA), therefore with a goat anti-rat IgG (H+L) Alexa Fluor
488 or a donkey anti-rabbit IgG (H+L) Alexa Fluor 594 sec-
ondary antibody (1:500, Thermo Fisher Scientific, USA). Slides
were closed with glass coverslips using mounting medium con-
taining DAPI (Prolong Gold with DAPI, Life Technologies,
Fig. 6 NeuN+ quantification in the spinal cord of EAE mice. a Panel
reports the immunofluorescence staining of NeuN+ cells in the spinal
cord of CTRL mice (first row), NBR-ISO-treated mice (second row),
NBR-anti-CD20-treated mice (third row), anti-CD20-treatedmice (fourth
row). Spinal cord sections were labelled with DAPI to detect cell nuclei in
blue (left column), NeuN to identify neurons in red (middle column) and
DAPI/NeuN+ merge (right column). Magnification: 40X; scale bar =
50 μm. b Statistics of NeuN+ quantification (% of NeuN+ cells/field)
in the spinal cord of the four groups of EAE mice. Mean ± SEM is re-
ported. Mann-Whitney statistical test was used (**p < 0.01; ****p <
0.0001)
USA). Slides were observed by light or fluorescence microscopy
(Leica Microsystems, Germany). The amount of B220+ and
NeuN+ cells in spinal cord was estimated manually (by ImageJ
Software, NIH, USA), expressing the count as B220+ cells per
mm2 (1 mm2 = half spinal cord slice approximately) or as
NeuN+ cells per field, on an average of 15 observed fields/
slide per mice group.
Ex Vivo Evaluation of B Cell Depletion
Spleen removed fromEAEmicewere put on nylon filters with
70 μm pores (BD Falcon) and smashed by mechanical disso-
ciation, followed by density gradient centrifugation (Biocoll,
BiochromAG).Mononuclear cells ring was manually isolated
and marked with anti CD19 PE monoclonal antibody
Fig. 7 Qualitative evaluation of
the axonal damage in mice spinal
cord by Bielschowsky staining.
Figure reports the Bielschowsky
staining on spinal cord sections in
the four groups of EAE mice:
CTRL (first row), NBR-ISO
(second row), NBR-anti-CD20
(third row), anti-CD20 (fourth
row) at 4X (left column; scale
bar = 500 μm) and paired 10X
(right column; scale bar =
200 μm) magnification
(Miltenyi Biotec, USA, 1:400). The evaluation of CD19+
cells was performed at 9 and 17 days post mice treatment by
CyFLow Space flowcytometer (Sysmex Partec, Gemany) and
FloMax® software (Sysmex Partec, Germany) and by LSR II
Fortessa flowcytometer (BD Bioscences, USA) and by means
of FACS Diva® software (BD Bioscences, USA) to acquire
data, respectively. FlowJo® software (Flowjo LLC, USA)
was used for the analysis.
Cytokines Production
Draining lymph nodes were removed, mononuclear cells were
isolated as described above, cells were seeded in 96-well U
bottom plates (Jet Biofil, China) at density of 2 × 105 cells/
well in complete medium (RPMI 1640 + 10% fetal bovine
serum +1% penicillin–streptomycin +1% sodium pyruvate
+1% L-glutamine +1% Hepes Buffer, Sigma), without stimu-
li, with MOG35–55 50 μg/mL for 72 h or PHA 5 μg/mL for
48 h. Incubation was performed by Heraeus 6000 (Heraeus,
Germany) incubator at 37 °C and 5% CO2. After incubation,
supernatants were collected from each well and cytokines
production was evaluated by Luminex® test (Merck
Millipore, Germany), following manufacturer’s protocol.
Proliferative Response
Cells isolated from spleen were seeded in 96-well U bottom
plates (Jet Biofil, China) at density of 2 × 105 cells/well in
complete medium, without stimuli, with MOG35–55 50 μg/
mL for 72 h or PHA 5 μg/mL for 48 h., as described for
Fig. 8 Cytokine profiles of EAE
lymph nodes T cells and
proliferative response of EAE
spleen cells. Graphs report the
level (pg/mL) of IFN-γ and IL-17
cytokines in ex vivo MOG35–55-
stimulated cells (a, c) or PHA-
stimulated cells (b, d). e
Splenocytes proliferation was de-
termined by 3H-thymidine incor-
poration assay and is expressed as
Δcpm (mean cpm observed in
MOG35–55-stimulated cells –
mean cpm in not stimulated cells;
cpm = counts per minute). Mean
± SEM is reported. Mann-
Whitney statistical test was used
(*p < 0.05; **p < 0.01; ns = not
significant)
cytokines production evaluation; 3H-thymidine 1 μCi/well
(Perkin Elmer, USA) was pulsed for 8 h. Later, cells were
harvested by means of Tomtec Harvester Mach III Cell
Harvester (TomTec, USA) on a glass fiber filters discs and
proliferative response was measured as counts per minute
(cpm) with a scintillation Trimux Microbeta 1450 counter
(Wallac). We considered the test positive when Δcpm was
>1000 cpm (Δcpm = cpm of stimulated wells − cpm of not-
stimulated wells).
Statistical Analysis
Statistical analysis was performed by GraphPad Prism®
Software (GraphPad Software Inc., USA). Mann-Whitney or
Friedman tests were used when appropriated. Statistical sig-
nificance was considered when p < 0.05.
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